XyloCor Therapeutics is focused on improving the lives of people with cardiovascular disease through our commitment to advancing the science of gene therapy.
Press Release: March 22, 2021
XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease
XyloCor’s proprietary products address significant unmet clinical needs in cardiovascular disease.
XyloCor’s products are enabled by proprietary gene therapy technologies from Weill Cornell Medical College.